Looking at a blood test to track heart health during HER2 breast cancer treatment
Part of Cancer, Heart & circulation, Injuries & trauma, Skin clinical trials.
This trial is checking if a simple blood test (NT-proBNP) can help spot early signs of heart side effects from certain breast cancer treatments (chemotherapy plus HER2 blockers). If successful, it might help doctors adjust treatment sooner to protect your heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer that is scheduled for treatment with chemotherapy and HER2-blocking drugs.
- You are 18 years or older.
- Your daily activity level is not severely limited (ECOG/WHO 0-1).
- Your organs are working well enough for the planned treatment, as judged by your doctor.
- The cancer has not spread to other parts of the body (no distant metastases).
- You have not had another cancer in the last 5 years, except for certain skin cancers or early cervical cancer.
- You are not pregnant and agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares whether special heart imaging or blood tests better helps monitor heart safety while you receive HER2-targeted therapy (like trastuzumab, with or without pertuzumab) plus chemotherapy. It may help doctors catch early heart stress and choose the safest treatment plan for you.
This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
This study looks at whether a simple blood test can spot early signs of heart damage from certain breast cancer treatments (anthracycline chemo or anti-HER2 drugs). The goal is to protect your heart while you get the cancer treatment you need.
This study is testing a way to use a simple blood test during chemotherapy to see how well the treatment is working in certain breast cancers. The goal is to make sure you get the best treatment for your tumor type.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.